soul trial oral semaglutide cardiovascular outcomes results 2024 Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

An oral formulation of semaglutide lowered the risk major adverse cardiovascular events by 14% in four years, with no change in safety profile compared to placebo, according to the SOUL study. #ACC25

20.62

★★★★☆4.8 (126)

Impact of Oral Semaglutide on Kidney Outcomes in People With Type Diabetes: Results From the SOUL Randomized Trial

23.04

★★★★★4.9 (98)

In patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8

27.33

★★★★★5.0 (157)

SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes

24.62

★★★★★4.7 (84)

Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study | Diabetes Therapy

20.57

★★★★★4.9 (203)

🔴Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants

22.56

★★★★★5.0 (176)

Projected reduction in major adverse cardiovascular events among high-risk U.S. adults with type 2 diabetes eligible for oral semaglutide: a SOUL trial–based analysis using NHANES (1988–2018) cycles

22.15

★★★★★4.8 (132)